Humoral and cellular immune responses to two and three doses of SARS-CoV-2 vaccines in rituximab-treated patients with rheumatoid arthritis: a prospective, cohort study

In rituximab-treated patients with rheumatoid arthritis, humoral and cellular immune responses after two or three doses of SARS-CoV-2 vaccines are not well characterised. We aimed to address this knowledge gap. This prospective, cohort study (Nor-vaC) was done at two hospitals in Norway. For this su...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	The Lancet. Rheumatology 2022-03, Vol.4 (3), p.e177-e187
Hauptverfasser:	Jyssum, Ingrid, Kared, Hassen, Tran, Trung T, Tveter, Anne T, Provan, Sella A, Sexton, Joseph, Jørgensen, Kristin K, Jahnsen, Jørgen, Kro, Grete B, Warren, David J, Vaage, Eline B, Kvien, Tore K, Nissen-Meyer, Lise-Sofie H, Anderson, Ane Marie, Grødeland, Gunnveig, Haavardsholm, Espen A, Vaage, John Torgils, Mjaaland, Siri, Syversen, Silje Watterdal, Lund-Johansen, Fridtjof, Munthe, Ludvig A, Goll, Guro Løvik
Format:	Artikel
Sprache:	eng
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	In rituximab-treated patients with rheumatoid arthritis, humoral and cellular immune responses after two or three doses of SARS-CoV-2 vaccines are not well characterised. We aimed to address this knowledge gap. This prospective, cohort study (Nor-vaC) was done at two hospitals in Norway. For this sub-study, we enrolled patients with rheumatoid arthritis on rituximab treatment and healthy controls who received SARS-CoV-2 vaccines according to the Norwegian national vaccination programme. Patients with insufficient serological responses to two doses (antibody to the receptor-binding domain [RBD] of the SARS-CoV-2 spike protein concentration
ISSN:	2665-9913 2665-9913
DOI:	10.1016/S2665-9913(21)00394-5